Post-Authorization Activity Table for Perjeta

The PAAT table describes post-authorization activity for Perjeta, a product which contains the medicinal ingredient pertuzumab. Based on Health Canada's review, the benefit/risk profile of Perjeta in combination with Herceptin (trastuzumab) and docetaxel is favourable for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Read more here.